While losing either RNF4 or USP7 insignificantly increased sensitivity to bortezomib, an FDA-approved therapeutic for multiple myeloma and mantel cell lymphoma [61], losing both genes rendered cells significantly more sensitive (figure 3a–c). This evidence concerns the gene RNF4 and plasma cell myeloma.